Isavuconazole activity against emerging fungal pathogens with reduced azole-susceptibility: Aspergillus lentulus, Neosartorya udagawae and Cryptococcus gattii.

DATTA, K; RHEE, P; BYRNES, E III; GARCIA, GUILLERMO; PERLIN, DAVID S.; STAAB, JF; MARR, KIEREN A.

JOURNAL OF CLINICAL MICROBIOLOGY

AMER SOC MICROBIOLOGY

Lugar: Washington; Año: 2013 vol. 51 p. 3090 - 3093

0095-1137

Isavuconazole is a second-generation extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus, Neosartorya udagawae and yeast Cryptococcus gattii VGII 29 (implicated in the US Pacific Northwest outbreak) exhibit reduced susceptibilities to several azoles, but higher susceptibility to isavuconazolein vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus, Neosartorya udagawae and yeast Cryptococcus gattii VGII 29 (implicated in the US Pacific Northwest outbreak) exhibit reduced susceptibilities to several azoles, but higher susceptibility to isavuconazole